REG - e-Therapeutics plc - Result of General Meeting

E-TherapeuticsAnnouncement

29/04/2024 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240429:nRSc4503Ma&default-theme=true

RNS Number : 4503M  e-Therapeutics plc  29 April 2024

 

 

 

e-therapeutics plc

("e-therapeutics" or "ETX" or the "Company")

 

Result of General Meeting

 Matched Bargain Settlement Facility

 

 

London, UK, 29 April 2024 - e-therapeutics plc (AIM: ETX), a company
integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that at the Company's General
Meeting held earlier today, all resolutions were duly passed.

 

Accordingly, pursuant to the passing of Resolution 3, cancellation of
admission of the Company's ordinary shares to trading on AIM will become
effective at 7.00 a.m. on 9 May 2024.

 

The Subscription remains conditional upon regulatory approval, specifically
the Subscription by M&G is conditional upon clearance under the National
Security and Investment Act 2021 ("NSIA"), by either the Secretary of State:
(i) having notified the parties pursuant to the NSIA that no further action
will be taken in relation to the Subscription; or (ii) making a final order
under the NSIA in respect of the Subscription, the provisions of which would
allow completion of the Subscription on terms reasonably satisfactory to
M&G. The Richard Griffiths Subscription and the M&G Subscription are
each conditional on the occurrence of the other, so the intention is that they
will complete at the same time, and further updates will be made on the
Company's website at www.etherapeutics.co.uk.

 

The votes were as follows:

 

 Resolution  Votes For    %      Votes     %     Abstentions  Resolution Result

                                 Against

 Ordinary 1  403,051,326  99.91  333,870   0.08  15,782       Passed
 Special 2   403,036,326  99.91  348,870   0.09  15,782       Passed
 Special 3   402,999,175  99.90  399,803   0.10  2,000        Passed

 

 

Shareholders are reminded that the last day of dealings in ETX's ordinary
shares on AIM will be 8 May 2024.

 

Matched Bargain Facility

To facilitate future shareholder transactions in the Company's ordinary
shares, the Company has appointed JP Jenkins to provide a matched bargain
facility, which will be available upon the date of Cancellation.

JP Jenkins ( www.jpjenkins.com (http://www.jpjenkins.com/)  ) is a trading
name of InfinitX Limited and Appointed Representative of Prosper Capital LLP
(FRN453007), which is authorised and regulated by the Financial Conduct
Authority. JP Jenkins will operate an electronic off-market dealing facility
for the ordinary shares. Under the Matched Bargain Facility, Shareholders or
persons wishing to acquire or dispose of Ordinary Shares will be able to leave
an indication with JP Jenkins, through their stockbroker (JP Jenkins is unable
to deal directly with members of the public), of the number of Ordinary Shares
that they are prepared to buy or sell at an agreed price. In the event that JP
Jenkins is able to match that order with an opposite sell or buy instruction,
it would contact both parties and then effect the bargain.

Upon Cancellation, full details of the matched bargain facility will be made
available to Shareholders on the Company's website at www.etherapeutics.co.uk
(http://www.etherapeutics.co.uk)

Shareholders will continue to be able to hold their shares in uncertificated
form (i.e. in CREST) and should check with their existing stockbroker whether
they are willing or able to trade in unquoted shares.

Shareholders should also be aware that the matched bargain facility could be
withdrawn at a later date. The provision of a matched bargain facility will be
kept under review by the Board and, in determining whether to continue to
offer a matched bargain facility, the Company shall consider expected (and
communicated) shareholder demand for such a facility as well as the
composition of the Company's register of members and the costs to the Company
and shareholders.

Unless otherwise defined, capitalised terms used in this announcement shall
have the same meaning as set out in the circular sent to shareholders dated 10
April 2024. A copy of the circular is available on the Company's website.

 

Enquiries

 

 e-therapeutics plc
 Ali Mortazavi,                                                                            Tel: +44 (0)20 4551 8888
 CEO

                                                                                         www.etherapeutics.co.uk
 Timothy Bretherton, CFO

      SP Angel Corporate Finance LLP                                                       Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover
and develop life-transforming medicines. ETX's proprietary RNAi chemistry
platform, GalOmic™, enables generation of specific, potent, and durable
siRNA therapeutics for effective silencing of novel gene targets in
hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to
discover better medicines faster through generation of novel insights and
increased automation across all stages of drug development. HepNet™
encompasses an extensive hepatocyte-specific knowledgebase and a suite of
advanced AI-driven approaches which enable identification of novel gene
targets, rapid target-indication assessment, and predictive in silico siRNA
design. The Company has specialist expertise and a robust position in applying
computation to biology. Its computational approaches have been extensively
validated through generation of data from pipeline programs and successful
drug discovery collaborations with biopharma companies, such as Novo Nordisk,
Galapagos NV, and iTeos Therapeutics.

 

Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is
progressing a therapeutic pipeline of highly differentiated RNAi candidates
across a variety of therapeutic areas with high unmet need. The Company has
generated positive proof-of-concept data on preclinical assets in metabolic
dysfunction-associated steatohepatitis (MASH), dry age-related macular
degeneration (dry AMD), haemophilia and, cardiometabolic disease, further
validating its computationally enhanced approach to research and development.
ETX is currently progressing lead assets ETX-312 for MASH and ETX-407 for dry
AMD through IND-enabling studies and towards the clinic.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMFLFIVSTIAFIS